Non-small-cell lung cancer (NSCLC), the most common type of lung cancer, is the leading cause of cancer deaths worldwide and few drug treatments exist.
The research, published in the journal Oncogene, investigated the effectiveness of breast cancer drugs called PARP inhibitors.
The findings revealed that the drugs killed cancerous cells and left the healthy ones intact, in up to half of NSCLC tumours.
Study author Dr Chris Lord said: “This study suggests that PARP inhibitors, treatments already in clinical trials to treat breast and ovarian cancer, could also be a promising treatment for patients with certain forms of lung cancer.
Learn about the factors that can cause lung disease and the ways to reduce your contact with them.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.